title: Effects of oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders.
abstract: Pretherapy sperm cryopreservation in young men is currently included in good clinical practice guidelines for cancer patients. The aim of this paper is to outline the effects of different oncological treatments on semen quality in patients with testicular neoplasia or lymphoproliferative disorders, based on an 8-year experience of the Cryopreservation Centre of a large public hospital. Two hundred and sixty-one patients with testicular neoplasia and 219 patients with lymphoproliferative disorders who underwent chemotherapy and/or radiotherapy and pretherapy semen cryopreservation were evaluated. Sperm and hormonal parameters (follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, inhibin B levels) were assessed prior to and 6, 12, 18, 24 and 36 months after the end of cancer treatment. At the time of sperm collection, baseline FSH level and sperm concentration were impaired to a greater extent in patients with malignant testicular neoplasias than in patients with lymphoproliferative disorders. Toxic effects on spermatogenesis were still evident at 6 and 12 months after the end of cancer therapies, while an improvement of seminal parameters was observed after 18 months. In conclusion, an overall increase in sperm concentration was recorded about 18 months after the end of cancer treatments in the majority of patients, even if it was not possible to predict the evolution of each single case 'a priori'. For this reason, pretherapy semen cryopreservation should be considered in all young cancer patients.
authors.affiliation: Department of Medical Sciences, University of Turin, Turin 10126, Italy. cataldo.dibisceglie@unito.it
authors.forename: Cataldo
authors.initials: C
authors.lastname: Di Bisceglie
authors.forename: Angela
authors.initials: A
authors.lastname: Bertagna
authors.forename: Emanuela R
authors.initials: ER
authors.lastname: Composto
authors.forename: Fabio
authors.initials: F
authors.lastname: Lanfranco
authors.forename: Matteo
authors.initials: M
authors.lastname: Baldi
authors.forename: Giovanna
authors.initials: G
authors.lastname: Motta
authors.forename: Anna M
authors.initials: AM
authors.lastname: Barberis
authors.forename: Emanuela
authors.initials: E
authors.lastname: Napolitano
authors.forename: Elena
authors.initials: E
authors.lastname: Castellano
authors.forename: Chiara
authors.initials: C
authors.lastname: Manieri
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D015925:Cryopreservation; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007265:Inhibins / Q000378:metabolism; D007986:Luteinizing Hormone / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism / Q000628:therapy*; D008297:Male; D011878:Radiotherapy / Q000009:adverse effects; D012661:Semen / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D055101:Semen Analysis; D013094:Spermatozoa / Q000187:drug effects* / Q000528:radiation effects*; D013736:Testicular Neoplasms / Q000378:metabolism / Q000628:therapy*; D013739:Testosterone / Q000378:metabolism; D013997:Time Factors
chemical_list: C422364:inhibin B; D013739:Testosterone; D007265:Inhibins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4831-41
references.pmid: 20458029
references.citation: Hum Reprod. 2006 Nov;21(11):2882-9
references.pmid: 16997940
references.citation: Cancer Treat Rev. 2007 Nov;33(7):609-15
references.pmid: 17398011
references.citation: Eur Urol. 2007 Aug;52(2):355-67
references.pmid: 17498866
references.citation: Eur Urol. 2005 Dec;48(6):885-94
references.pmid: 16126333
references.citation: Fertil Steril. 2009 Jun;91(6):2344-8
references.pmid: 18554588
references.citation: Eur Urol. 2005 Nov;48(5):779-85
references.pmid: 15963629
references.citation: Hum Reprod. 2003 Apr;18(4):796-801
references.pmid: 12660273
references.citation: J Urol. 1997 Sep;158(3 Pt 1):844-50
references.pmid: 9258096
references.citation: Fertil Steril. 2009 Jun;91(6):2481-6
references.pmid: 18440530
references.citation: Int J Urol. 2010 Apr;17(4):327-31
references.pmid: 20202000
references.citation: J Natl Cancer Inst Monogr. 2005;(34):12-7
references.pmid: 15784814
references.citation: Eur J Obstet Gynecol Reprod Biol. 2004 Apr 5;113 Suppl 1:S2-6
references.pmid: 15041121
references.citation: Hum Reprod Update. 2001 Jul-Aug;7(4):370-7
references.pmid: 11476349
references.citation: Lancet Oncol. 2005 Apr;6(4):209-18
references.pmid: 15811616
references.citation: Asian J Androl. 2006 Sep;8(5):515-33
references.pmid: 16847527
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2917-31
references.pmid: 16651642
references.citation: J Clin Oncol. 1999 Mar;17(3):941-7
references.pmid: 10071288
references.citation: Asian J Androl. 2010 May;12(3):356-62
references.pmid: 20348941